Bioventix (BVXP) AI Stock Analysis

• Market Cap: £154.13M
• Dividend Yield: 5.32%
• Average Volume (3M): 8.84K
• Price to Earnings (P/E): 19.6
• Beta (1Y): 0.29
• Revenue Growth: 0.49%
• EPS Growth: -9.52%
• Country: UK
• Employees: 17
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): 1.50
• Shares Outstanding: 5,224,860
• 10 Day Avg. Volume: 7,432
• 30 Day Avg. Volume: 8,835
• PEG Ratio: -2.51
• Price to Book (P/B): 11.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 15.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 78 Outperform
• Price Target: ―

Bioventix is in a strong financial position with excellent profitability and a robust balance sheet. Despite technical pressure, its fair valuation and high dividend yield provide a compelling investment case. Recent corporate events further bolster confidence in its growth potential.

Bioventix Business Overview & Revenue Model

Company Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

How the Company Makes Money

Bioventix makes money by licensing its proprietary antibodies to global diagnostics companies that incorporate them into their own diagnostic testing systems. The company generates revenue through upfront fees, milestone payments, and royalties based on the sales of diagnostic products that utilize its antibodies. These revenue streams are bolstered by long-term relationships with major diagnostics companies and continuous development of novel antibodies to meet emerging market needs. Bioventix's focus on high-quality, niche antibody products helps secure a competitive position and steady demand within the diagnostics industry.

Bioventix Financial Statement Overview

Summary

Bioventix demonstrates strong profitability with impressive margins, a debt-free balance sheet, and robust cash flow management. The company shows consistent growth and stability, positioning it well within the biotechnology industry.

Income Statement

Bioventix demonstrates strong profitability with impressive gross and net profit margins. The company has shown consistent revenue growth over the years, with a notable increase of 6.17% from 2023 to 2024. Additionally, EBIT and EBITDA margins are robust, indicating effective operational management.

Balance Sheet

The balance sheet of Bioventix is exceptionally strong, characterized by a zero-debt position which eliminates financial leverage risks. The company has a high equity ratio, reflecting solid financial stability. Return on Equity remains impressive, showcasing efficient utilization of equity to generate profits.

Cash Flow

Bioventix displays healthy cash flow management with consistent free cash flow generation and a solid operating cash flow to net income ratio. The free cash flow has shown growth and remains well-aligned with net income, highlighting efficient cash conversion.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
13.61M	12.82M	11.72M	10.93M	10.31M
	Gross Profit
12.57M	11.86M	10.87M	9.98M	9.36M
	EBIT
10.60M	10.04M	9.16M	8.35M	7.96M
	EBITDA
10.74M	10.20M	9.32M	8.22M	8.11M
	Net Income Common Stockholders
8.10M	8.37M	7.67M	6.73M	7.20M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.00M	5.72M	6.13M	6.49M	8.08M
	Total Assets
13.73M	13.28M	13.12M	12.91M	13.30M
	Total Debt
0.00	0.00	0.00	0.00	0.00
	Net Debt
-6.00M	-5.72M	-6.13M	-6.49M	-8.08M
	Total Liabilities
1.73M	1.22M	1.30M	1.09M	778.87K
	Stockholders Equity
12.00M	12.06M	11.82M	11.82M	12.52M
Cash Flow		Free Cash Flow
8.53M	7.89M	7.55M	6.11M	7.38M
	Operating Cash Flow
8.55M	7.90M	7.56M	6.37M	7.72M
	Investing Cash Flow
-15.91K	-10.58K	-11.76K	-259.83K	-561.28K
	Financing Cash Flow
-8.25M	-8.30M	-7.92M	-7.69M	-5.62M

Bioventix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2850.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Positive. The current price of 2850 is above the 20-day moving average (MA) of 2744.00, above the 50-day MA of 2616.45, and below the 200-day MA of 3239.80, indicating a neutral trend. The MACD of 78.26 indicates Negative momentum. The RSI at 60.28 is Neutral, neither overbought nor oversold. The STOCH value of 76.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BVXP.

Bioventix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	78 Outperform	£154.13M	19.63	69.08%	5.32%	0.49%	-9.52%
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%
AVCT		£115.91M	―	-73.02%	―	―	―
AREC	52 Neutral	£16.24M	―	-137.62%	―	10.50%	-9.60%
SCLP	46 Neutral	£95.90M	―	167.16%	―	-100.00%	-23.91%
OBD	40 Underperform	£6.36M	―	-222.16%	―	24.71%	38.28%
4BB		£174.06M	―		―	―	―

Bioventix Corporate Events

Bioventix CFO Increases Stake Through Share Purchase

Bioventix plc announced that its Chief Financial Officer, Bruce Hiscock, purchased 31 ordinary shares of the company at an average price of 2,632 pence per share through a dividend reinvestment plan. This transaction, which increases Hiscock’s beneficial interest to 1,205 ordinary shares, represents approximately 0.02% of the company’s issued share capital and is disclosed in compliance with the EU Market Abuse Regulation.

Spark’s Take on GB:BVXP Stock

According to Spark, TipRanks’ AI Analyst, GB:BVXP is a Outperform.

Bioventix is in a strong financial position with excellent profitability and a robust balance sheet. Despite technical pressure, its fair valuation and high dividend yield provide a compelling investment case. Recent corporate events further bolster confidence in its growth potential.

To see Spark’s full report on GB:BVXP stock, click here.

Bioventix CEO Increases Stake with Option Exercise

Bioventix plc announced that CEO Peter Harrison exercised options for 5,204 ordinary shares at a price of 1,350 pence each, increasing his total shareholding to 302,292 shares, representing a 5.79% interest in the company. The new shares will be admitted to trading on AIM, bringing the total number of ordinary shares in issue to 5,224,860, all with equal voting rights. This transaction reflects confidence in the company’s operations and may impact its market positioning by increasing shareholder engagement.

Spark’s Take on GB:BVXP Stock

According to Spark, TipRanks’ AI Analyst, GB:BVXP is a Outperform.

Bioventix exhibits strong financial health with commendable profitability and a robust balance sheet, which are significant strengths. Although the stock is currently under technical pressure, its fair valuation and attractive dividend yield provide a positive investment case. Corporate events indicate promising future growth, contributing to an overall favorable outlook.

To see Spark’s full report on GB:BVXP stock, click here.

Bioventix Reports Steady Revenue with Promising Future Prospects

Bioventix reported a 1% increase in revenue to £6.73 million for the six months ending December 2024, though profit before tax fell by 4% due to increased R&D spending. Despite steady sales in core antibodies, including vitamin D and troponin, the company is optimistic about future growth driven by increased sales of Tau antibodies for Alzheimer’s disease testing and ongoing research in industrial pollution and water quality projects. The interim dividend rose by 3% to 70p per share, reflecting the company’s commitment to shareholder returns. Bioventix anticipates a return to growth in 2026 as new applications for their antibodies gain traction, particularly in neurological blood testing and industrial applications.